Optimized strategy for in vivo Cas9-activation in <i>Drosophila</i>.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28808002.
- Also identified by DOI 10.1073/pnas.1707635114 and PMC identifier 5584449.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
While several large-scale resources are available for in vivo loss-of-function studies in <i>Drosophila</i>, an analogous resource for overexpressing genes from their endogenous loci does not exist. We describe a strategy for generating such a resource using Cas9 transcriptional activators (CRISPRa). First, we compare a panel of CRISPRa approaches and demonstrate that, for in vivo studies, dCas9-VPR is the most optimal activator. Next, we demonstrate that this approach is scalable and has a high success rate, as >75% of the lines tested activate their target gene. We show that CRISPRa leads to physiologically relevant levels of target gene expression capable of generating strong gain-of-function (GOF) phenotypes in multiple tissues and thus serves as a useful platform for genetic screening. Based on the success of this CRISRPa approach, we are generating a genome-wide collection of flies expressing single-guide RNAs (sgRNAs) for CRISPRa. We also present a collection of more than 30 Gal4 > UAS:dCas9-VPR lines to aid in using these sgRNA lines for GOF studies in vivo.
Medical subject headings
- CRISPR-Cas Systems
- Drosophila melanogaster
- Transcription Factors
- Transcriptional Activation